Mathew Cholankeril, MD
Cardiovascular Disease · Rahway, NJNPI 1588694780
Payments from drug & device makers
Across 306 payments — averaging $55.35 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GE HealthCare$7K
- Abbott$3K
- AstraZeneca$2K
- Baxter Healthcare$709
- Novartis$579
- ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$431
- plus $3K from 30 others
What the payments were for
- Consulting fees$450%
- Speaking & faculty fees$6,97641%
- Food & beverage$9,20154%
- Education$220%
- Other$6934%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| GE HealthCare | 1 | $6,776 |
| Abbott | 50 | $2,783 |
| AstraZeneca | 58 | $2,233 |
| Baxter Healthcare | 2 | $709 |
| Novartis | 36 | $579 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 14 | $431 |
| Biotronik Inc. | 6 | $411 |
| Merck | 22 | $323 |
| Novo Nordisk | 20 | $277 |
| Shockwave Medical, Inc | 3 | $256 |
| Medtronic(2 entities) | 10 | $235 |
| Boston Scientific | 3 | $217 |
| Vifor Pharma, Inc. | 1 | $200 |
| Boehringer Ingelheim | 11 | $178 |
| Bayer | 8 | $172 |
| Johnson & Johnson | 9 | $145 |
| Abiomed | 3 | $121 |
| Amarin Pharma, Inc. | 8 | $117 |
| E.r. Squibb & Sons, L.L.C. | 8 | $108 |
| Kowa Pharmaceuticals America, Inc. | 1 | $102 |
| Pfizer | 7 | $101 |
| Scpharmaceuticals Inc. | 2 | $67 |
| Lexicon Pharmaceuticals, Inc. | 3 | $55 |
| Lilly USA, LLC | 3 | $40 |
| Daiichi Sankyo Inc. | 2 | $40 |
| Cordis US CORP. | 3 | $39 |
| Acist Medical Systems, Inc. | 1 | $35 |
| Penumbra, Inc. | 2 | $34 |
| Bardy Diagnostics, Inc. | 1 | $30 |
| Amgen | 2 | $29 |
| Atricure, Inc. | 1 | $24 |
| Edwards Lifesciences | 1 | $18 |
| Mannkind Corporation | 1 | $15 |
| Otsuka America Pharmaceutical, Inc. | 1 | $13 |
| GSK | 1 | $13 |
| Althera Pharmaceuticals LLC | 1 | $10 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- FARXIGA$775
- BRILINTA$502
- AVEIR$371
- JOT DX$349
- BREZTRI$274
- Fortify Assura, Ellipse ICD$241
- GALLANT$216
- Veltassa$200
- BREZTRI AEROSPHERE$146
- BEVESPI AEROSPHERE$146
- Assurity Pacemaker$142
- Vascular Lithotripsy$138
- LUX-Dx Insertable Cardiac Monitor$136
- Quadra Allure MP RF CRT Pacemkr$105
- DURATA$105
- Seglentis$102
- ENTRESTO$100
- LifeVest$100
How this compares
$16,937 in reported general payments places this provider in the 80th percentile of 1,006 cardiovascular disease providers in New Jersey.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 178 | $216,146 |
| BrilintaTicagrelor | 100 | $96,501 |
| OzempicSemaglutide | 40 | $70,669 |
| JardianceEmpagliflozin | 56 | $70,511 |
| XareltoRivaroxaban | 50 | $68,576 |
| EntrestoSacubitril/Valsartan | 28 | $43,106 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 32 | $21,732 |
| FarxigaDapagliflozin Propanediol | 17 | $20,086 |
| TrulicityDulaglutide | 15 | $16,729 |
| TradjentaLinagliptin | 17 | $11,545 |
| Breo ElliptaFluticasone/Vilanterol | 24 | $11,352 |
| Metoprolol Succinate | 612 | $7,898 |
| Rosuvastatin Calcium | 452 | $7,157 |
| Atorvastatin Calcium | 546 | $6,210 |
| ClopidogrelClopidogrel Bisulfate | 408 | $4,639 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $101 | $216,146178 claims |
| AstraZenecaBrilinta, Farxiga | $2,233 | $116,587117 claims |
| Boehringer IngelheimJardiance, Tradjenta | $178 | $82,05573 claims |
| Novo NordiskOzempic | $277 | $70,66940 claims |
| Johnson & JohnsonXarelto | $145 | $68,57650 claims |
| NovartisEntresto | $579 | $43,10628 claims |
| GSKTrelegy Ellipta, Breo Ellipta | $13 | $33,08456 claims |
| Lilly USA, LLCTrulicity | $40 | $16,72915 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 1,006 cardiovascular disease providers in New Jersey.
Other cardiovascular disease in Rahway
- Robert KippermanMorristown$5.3M
- Sharan MahalBridgewater$3.5M
- Linda GillamMorristown$2.2M
- Mark GelerntHaddon Heights$2M
- Robert FishbergSpringfield$1.9M
- Dilip ViswanathHaddon Heights$1.8M
- Marc CohenNewark$1M
- Jasjit WaliaElizabeth$859K
- Sajjad SabirCamden$742K
- John CovaleskyManalapan$716K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.